´ëÇÑ°íÇ÷¾ÐÇÐȸ Æó°íÇ÷¾Ð¿¬±¸È¸ Á¦5ȸ ¿¬·ÊÇмú½ÉÆ÷Áö¾ö : 2020-10-31±³À°ÀÏÀÚ : 2020-10-31
±³À°Àå¼Ò : ºû°íÀ» Àü³²´ëÇб³º´¿ø 2Ãþ ´ë°´ç
±³À°ÁÖÁ¦ :
´ëÇÑ°íÇ÷¾ÐÇÐȸ Æó°íÇ÷¾Ð¿¬±¸È¸ Á¦5ȸ ¿¬·ÊÇмú½ÉÆ÷Áö¾ö ÁÖÃÖ±â°ü : ´ëÇÑ°íÇ÷¾ÐÇÐȸ
´ã´çÀÚ : Á¤º°
¿¬¶ôó : 02-565-3350
À̸ÞÀÏ :
ksh2@koreanhypertension.org ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
±¤ÁÖ±¤¿ª½Ã±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 10,000¿ø
ºñ°í »çÀüµî·Ïºñ 10,0000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 09:00~09:15 Persistent pulmonary hypertension of newborn ¼ÛÀº¼Û(Àü³²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 09:15~09:30 Bronchopulmonary dysplasia and pulmonary hypertension in preemies °íÈÆ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 09:30~09:45 Pulmonary hypertension in young adults ÃÖÁ¤Çö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 09:45~10:00 Pulmonary hypertension in middle ages ±èÇö¼÷(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 10:00~10:15 Pulmonary hypertension in elderly ÀÌÀç½Â(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 10:15~10:30 Discussion Á¤ÁßÈ,¾È°æÁø,À̼±È(Á¶¼±ÀÇ´ë,°¡ÃµÀÇ´ë,ÀüºÏÀÇ´ë)
ÈÞ½Ä 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 10:30~10:50 Coffee break ()
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 10:50~11:05 Phosphodiesterase 5 inhibitor Àå¼ÒÀÍ(¼¼Á¾º´¿ø)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 11:05~11:20 Endothelin receptor blocker ±èÅÂÁ¾(Àü³²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 11:20~11:35 Prostanoid, parenteral ±è±â¹ü(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 11:35~11:50 Prostanoid, oral ¹ÚÀçÇü(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 11:50~12:05 Best combination treatment strategy for effective treatment ±è°æÈñ(¼¼Á¾º´¿ø)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 12:05~12:20 Discussion ½Å¼ºÈñ,³ªÁø¿À,¼ÕÁ¤¿ì,Çã¶õ(ÀÎÇÏÀÇ´ë,°í·ÁÀÇ´ë,¿øÁÖÀÇ´ë,ÇѾçÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 12:20~13:20 Lunch ()
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 13:20~13:35 Indication and completion of lung transplantation, in practice ±èȣö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 13:35~13:50 Outcomes of lung transplantation in the world and Korea À念¿ì(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 13:50~14:05 Follow-up guideline after lung transplantation including rehabilitation ±è¼ÛÀÌ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 14:05~14:20 Heart and lung co-transplantation ¹Ú±¹¾ç(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 14:20~14:35 Pearls and Pitfalls in lung transplantation from my experience ÀÌÁø±¸(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 14:35~14:50 Discussion À̼ö¿ë,±èÇöÁø(ºÎ»êÀÇ´ë,ÇѾçÀÇ´ë)
ÈÞ½Ä 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 14:50~15:10 Coffee break ()
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 15:10~15:25 How to find new target in PAH by microarray? º¯°æÈñ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 15:25~15:40 How to visualize macrophage mediated inflammation in pulmonary circulation? ÆØÁøö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 15:40~15:55 Why we need deep phenotyping in PAH on the era of multi-omics? Á¤¿íÁø(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 15:55~16:10 Discussion ¼Õ±¹Èñ,ÀÌÁÖÈñ,¿À¼¼¿¬(°¡ÃµÀÇ´ë,ÃæºÏÀÇ´ë,À̱濩¾Ï´ç´¢¿¬±¸¿ø)
ÈÞ½Ä 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 16:10~16:20 Interesting case discussions with brief review-case1 Â÷½½±â(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 16:20~16:30 Interesting case discussions with brief review-case2 ¹Ú¼öÁ¤(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 16:30~16:40 Interesting case discussions with brief review-case3 ÀåÇ×Á¦(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 16:40~16:50 Interesting case discussions with brief review-case4 ±èÁö³ª(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 16:50~17:00 Interesting case discussions with brief review-case5 ÀÌâÈÆ(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ 2Ãþ ´ë°´ç 17:00~17:10 Interesting case discussions with brief review-case6 ³ª½Â¿ø(¿ï»êÀÇ´ë)